Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
| العنوان: | Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study |
|---|---|
| المؤلفون: | Campiglio, M., Bufalino, R., Sandri, M., Ferri, E., Aiello, R. A., De Matteis, A., Mottolese, M., De Placido, S., Querzoli, P., Jirillo, A., Bottini, A., Fantini, M., Bonetti, A., Pedani, F., Mauri, M., Molino, A., Ferro, A., Pupa, S. M., Sasso, M., Ménard, S., Balsari, A., Tagliabue, E., Mustacchi, Giorgio, Zanconati, Fabrizio, Demetra, Group |
| المساهمون: | Fondazione IRCCS Istituto Nazionale dei Tumori, Humanitas Centro Catanese di Oncologia, Istituto Nazionale Tumori, Istituto Tumori Regina Elena, Università degli studi di Napoli Federico II, Università degli Studi di Ferrara (UniFE), Oncologia Medica 2, Istituto Oncologico Veneto IRCCS, Azienda Istituti Ospedalieri Cremona, Ospedali degli Infermi, Azianda USL-Rimini, Ospedale Mater Salutis, Ospedale San Giovanni, Ospedale San Giovanni-Addolorata, University of Verona (UNIVR), Ospedale Santa Chiara, Dipartimento di Morfologia Umana e Scienze Biomediche 'Città Studi', Università degli Studi di Milano [Milano] (UNIMI), Campiglio, M., Bufalino, R., Sandri, M., Ferri, E., Aiello, R. A., DE MATTEIS, Maria Antonietta, Mottolese, M., DE PLACIDO, Sabino, Querzoli, P., Jirillo, A., Bottini, A., Fantini, M., Bonetti, A., Pedani, F., Mauri, M., Molino, A., Ferro, A., Pupa, S. M., Sasso, M., Ménard, S., Balsari, A., Tagliabue, E., De Matteis, A., De Placido, S., Mustacchi, Giorgio, Zanconati, Fabrizio, Demetra, Group, Università di Ferrara |
| المصدر: | Breast Cancer Research and Treatment Breast Cancer Research and Treatment, Springer Verlag, 2011, 128 (1), pp.147-154. ⟨10.1007/s10549-011-1484-4⟩ |
| بيانات النشر: | HAL CCSD, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Oncology, Adult, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Breast Neoplasms, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, NO, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, breast cancer, Trastuzumab, Internal medicine, HER2, Propensity score matching, Clinical endpoint, Medicine, Humans, Neoplasm Metastasis, skin and connective tissue diseases, neoplasms, 030304 developmental biology, Retrospective Studies, 0303 health sciences, Predictive marker, trastuzumab, propensity score matching, business.industry, Proportional hazards model, Middle Aged, HER2, Trastuzumab, Metastatic breast cancer, RECIST, Propensity score matching, medicine.disease, Metastatic breast cancer, 3. Good health, Surgery, Treatment Outcome, RECIST, 030220 oncology & carcinogenesis, Female, Breast disease, business, medicine.drug |
| الوصف: | International audience; Recent studies have reported the potential clinical utility for metastatic breast cancer (MBC) patients of continuing trastuzumab beyond progression. Based on those results, here the authors have examined the benefits of trastuzumab-continuation by specifically evaluating RECIST responses upon first line trastuzumab-treatment as a potential predictive marker for therapeutic effect of trastuzumab-continuation beyond metastatic disease progression. The authors carried out a retrospective analysis of 272 HER2 positive MBC patients under trastuzumab treatment at 22 different oncology Italian centers during the years of 2000 and 2001 who progressed under first line trastuzumab-treatment. The primary end point of the study was the survival from the date of first documented progression upon first line trastuzumab treatment of disease. Data analysis involved the use of matching on propensity score to balance variables between treated and untreated subjects and to reduce bias. Of the 272 HER2-positive MBC patients, 154 (56.6%) continued treatment. 79 (51.3%) of those 154 patients showed responses based on RECIST criteria during first-line trastuzumab-treatment. Of the 118 patients that suspended trastuzumab, RECIST responses had been observed in 44 (37.3%). Cox proportional hazards analysis of progressed patients, matched using propensity score, showed that discontinuation of trastuzumab at metastatic disease progression was a risk factor for significantly reduced overall survival in both responder (HR = 2.23; 95% CI = 1.03-4.82) and non-responder groups (HR = 3.53, 95% CI = 1.73-7.21), with no significant differences in the two estimated HRs (-value of the likelihood-ratio test = 0.690). Continued trastuzumab treatment after disease progression has clinically and statistically significant effects in both RECIST responder and non-responder MBC patients. |
| وصف الملف: | STAMPA |
| اللغة: | English |
| تدمد: | 0167-6806 1573-7217 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aa40a1fe9257d22c165c558b8b7addaTest https://hal.archives-ouvertes.fr/hal-00630792Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1aa40a1fe9257d22c165c558b8b7adda |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 01676806 15737217 |
|---|